In this article, we will discuss the 10 Best Up and Coming Stocks with Highest Upside Potential.
On April 29, Steven Wieting, CIO Group Chief Investment Strategist, joined CNBC’s ‘Closing Bell Overtime’ to discuss the current market landscape where investors appear to be using AI as an “escape hatch” to look past significant headwinds, including closed straits, oil priced at $100, and rising Treasury yields. Wieting explained that the AI trade in software and hardware remains largely independent of the cyclical economy because major capital expenditure plans are already funded and established. These investments are moving forward regardless of fluctuations in consumer spending, travel, industrial activity, or the performance of cyclical companies in Europe and Asia.
However, Wieting noted that the global economy is increasingly feeling the wear and tear of geopolitical disruptions. He warned that as long as transportation routes remain shut, the economy will eventually hit binding constraints because moving goods requires oil and energy. He points out that the price of oil for delivery at the end of the year has moved $15 higher, signaling a growing problem for cyclical industries worldwide. While Wieting’s investments are not currently focused on Europe or Asia, he acknowledged that these regions feel the pinch more directly than the US and will be the primary beneficiaries once transportation and infrastructure issues are resolved.
Wieting highlighted a unique market environment characterized by both a boom and a shock occurring simultaneously. The boom is driven by an expected 88% gain in semiconductor EPS in the US and massive infrastructure spending. He noted that the four largest public company spenders recently increased their full-year capital expenditure by $94 billion, with further updates expected shortly. This heavy spending, combined with the energy supply shock, is pushing toward higher nominal growth, though Wieting laments that much of this growth is being driven by inflation.
Our Methodology
We used screeners to identify stocks that have gone public in the last 5 years and have an average upside potential of at least 25%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Up and Coming Stocks with Highest Upside Potential
10. Belite Bio (NASDAQ:BLTE)
Average Upside Potential: 29.31%
Belite Bio (NASDAQ:BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio begun a rolling submission of an NDA to the FDA for tinlarebant, a potential first-ever treatment for Stargardt disease type 1/STGD1. This rare, progressive genetic disorder leads to legal blindness and currently has no approved therapeutic options. Using its Breakthrough Therapy Designation, Belite expects to complete the full application by Q2 2026.
The submission is supported by data from the Phase 3 DRAGON trial, which showed tinlarebant’s ability to slow retinal degeneration. As an oral therapy, tinlarebant works by reducing the levels of serum retinol binding protein 4/RBP4, effectively limiting the accumulation of vitamin A-based toxins in the eye. Beyond Stargardt disease, the drug is also being investigated for its potential to treat geographic atrophy, an advanced form of dry age-related macular degeneration.
In anticipation of a potential launch in 2027, the company is scaling its commercial infrastructure, including market access, medical affairs, and sales teams. Belite Bio remains focused on working closely with the FDA throughout the review process to address the significant unmet medical needs of the Stargardt community.
Belite Bio is a clinical-stage drug development company advancing novel oral therapeutics for degenerative retinal and metabolic diseases with significant unmet medical needs. Its lead candidate, tinlarebant, targets the reduction of bisretinoid toxins and is currently undergoing multiple clinical trials for Stargardt disease and geographic atrophy.
9. PACS Group Inc. (NYSE:PACS)
Average Upside Potential: 34.43%
PACS Group Inc. (NYSE:PACS) is one of the best up and coming stocks with highest upside potential. On April 27, PACS Group appointed Carey P. Hendrickson as its Chief Financial Officer. Hendrickson, a seasoned financial leader with nearly 40 years of experience, succeeds co-founder Mark Hancock, who had served as interim CFO since September 2025. Hancock will retire from his executive role by June 30, but will remain on the Board of Directors as Vice Chairman.
Hendrickson joins the post-acute healthcare platform from US Physical Therapy Inc. (NYSE:USPH), where he served as CFO, overseeing financial operations for nearly 800 clinics across 44 states. His background also includes six years as CFO of Capital Senior Living Corporation, where he managed financial strategies for one of the largest senior living operators in the country. His extensive experience in regulated healthcare environments and M&A integration is expected to be a key asset as PACS Group Inc. continues to expand its national footprint.
CEO Jason Murray highlighted Hendrickson’s strategic acuity and record of navigating complex market cycles as essential for the company’s current growth trajectory. Hendrickson expressed his commitment to contributing to the company’s mission of delivering clinical excellence at scale, joining the executive team at a pivotal moment for the organization’s financial infrastructure and sustainable growth plans.
PACS Group Inc. is one of the largest post-acute healthcare platforms in the US, supporting facilities and ancillary services across 17 states. The company operates over 320 facilities serving more than 31,700 patients daily with a mission to revolutionize the quality of post-acute care.
8. Amentum Holdings Inc. (NYSE:AMTM)
Average Upside Potential: 37.80%
Amentum Holdings Inc. (NYSE:AMTM) is one of the best up and coming stocks with highest upside potential. On April 13, Amentum played a pivotal role in NASA’s Artemis II mission, providing the critical ground systems operations required for the program’s first crewed flight. The company’s responsibilities at Kennedy Space Center spanned the entire mission lifecycle, including driving the iconic Crawler Transporter, integrating the Space Launch System/SLS with the Mobile Launcher, and conducting the mission’s comprehensive Wet Dress Rehearsal. These efforts were essential in validating the safety and reliability of the vehicle before its historic journey toward the Moon.
Additionally, Amentum managed high-stakes operations such as precision hypergolic servicing (rocket fuel management) and the deployment of NASA’s Emergency Escape System. Their technical support extended to the scientific research and testing phases of various Artemis program elements, ensuring that the Orion spacecraft and SLS met all mission-critical performance standards. Mark Walter, president of Amentum’s Engineering & Technology business, emphasized that the company’s operational excellence was a key driver in enabling this milestone for deep-space exploration.
Amentum Holdings Inc.’s (NYSE:AMTM) involvement also included the post-mission recovery phase, where they assisted NASA and the US Navy in retrieving the Orion spacecraft from the Pacific Ocean. This end-to-end support underscores Amentum’s long-standing partnership with NASA as a global leader in advanced engineering.
Amentum Holdings Inc. is a business services company that specializes in engineering and technology solutions through two segments: Digital Solutions and Global Engineering Solutions.
7. ABIVAX Société Anonyme (NASDAQ:ABVX)
Average Upside Potential: 37.83%
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks with highest upside potential. On March 23, Abivax reported its full-year 2025 financial results, highlighting steady clinical progress for its lead drug candidate, obefazimod. Following a major $700.3 million public offering in July 2025, the company ended the year with €530.4 million in cash and short-term investments. This liquidity provides a projected cash runway into Q4 2027, allowing Abivax to fully fund its pivotal trials and prepare for potential commercialization.
Operationally, the company’s Phase 3 ABTECT-UC maintenance trial for ulcerative colitis remains the primary focus. An independent safety review in March confirmed no new safety signals, with nearly 90% of patients having completed the 44-week treatment period. Topline results from this trial are expected in late Q2 2026, with a potential NDA submission targeted for Q4 2026, contingent on positive data.
To lead its transition from a clinical-stage to a commercial-stage entity, Abivax made several high-profile leadership appointments, most notably naming Michael Nesrallah as Chief Commercial Officer. Nesrallah brings deep expertise in the inflammatory bowel disease/IBD market from his previous tenure at Takeda. While the company reported a net loss of €336.1 million for 2025 (largely driven by increased R&D and non-cash expenses related to its share price appreciation) the retirement of its senior convertible notes and other debt tranches has simplified the balance sheet for the next phase of growth.
ABIVAX Société Anonyme develops therapeutics targeting chronic inflammatory diseases.
6. Core Scientific Inc. (NASDAQ:CORZ)
Average Upside Potential: 38.46%
Core Scientific Inc. (NASDAQ:CORZ) is one of the best up and coming stocks with highest upside potential. On April 27, Core Scientific announced a significant expansion of its Pecos, Texas campus, targeting a gross power capacity of 1.5 GW, with approximately 1.0 GW designated as leasable. The company is currently transitioning the site from its original use in bitcoin mining to HDC for AI infrastructure. Vertical construction is already underway, with the first data hall reaching foundational milestones and on track for an early 2027 delivery.
To support this massive scale-up, Core Scientific has secured an additional 300 MW of gross power through its utility provider and acquired over 200 acres of land. A key component of the expansion is a scalable behind-the-meter solution, which allows the company to provide additional capacity outside its previously announced leasable pipeline. This strategy uses Core Scientific’s existing control over power and infrastructure to rapidly meet the growing demand for specialized AI data centers.
CEO Adam Sullivan noted that the expansion in Pecos highlights the company’s ability to differentiate its infrastructure build-outs through in-house expertise. By scaling in a market where they already maintain operational control, Core Scientific Inc. aims to maximize speed-to-market. The Pecos campus is currently available for lease as the company moves forward with the next phase of its multi-tiered transformation.
Core Scientific Inc. operates digital Bitcoin mining and HPC infrastructure. The company uses its own fleet of computers, called miners, to earn Bitcoin for its own account and also provides hosting services for Bitcoin mining and high-performance computing customers at US-based operational data centers.
5. Tempus AI Inc. (NASDAQ:TEM)
Average Upside Potential: 41.04%
Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual patient visits across the USC Norris Comprehensive Cancer Center, Keck Hospital of USC, and other affiliated clinics.
By combining Tempus’ AI-powered diagnostic platform with USC’s clinical expertise, the organizations intend to create a seamless ecosystem that prioritizes personalized care and improves long-term patient outcomes. The collaboration is built upon four foundational pillars: clinical testing, clinical trial matching, care gap pathways, and research co-development.
Through these initiatives, Tempus AI Inc. will integrate advanced molecular diagnostics into Keck Medicine’s workflows and utilize its TIME Trial Program to automate the identification of patients eligible for targeted therapies. Furthermore, AI-driven insights will be deployed to identify and close existing gaps in patient care, ensuring that clinical innovations move responsibly and efficiently from academic research into daily medical practice.
Tempus AI Inc. is a healthcare technology company that uses artificial intelligence to advance precision medicine.
4. Nuvalent (NASDAQ:NUVL)
Average Upside Potential: 41.11%
Nuvalent (NASDAQ:NUVL) is one of the best up and coming stocks with highest upside potential. On April 7, Nuvalent submitted an NDA to the FDA for neladalkib, its investigational ALK-selective inhibitor for patients with advanced ALK-positive non-small cell lung cancer/NSCLC who have previously been treated with tyrosine kinase inhibitors/TKIs. This submission comes less than four years after the initiation of the first clinical trial, reflecting an accelerated development timeline supported by the FDA’s Breakthrough Therapy Designation.
The application is supported by data from the ALKOVE-1 Phase 1/2 clinical trial. In pre-treated patients, neladalkib showed robust anti-tumor activity, including responses in patients with brain metastases. Crucially, the drug’s “ALK-selective, TRK-sparing” design aims to overcome resistance mutations (such as G1202R) caused by earlier-generation inhibitors while avoiding the neurological side effects often associated with off-target TRK inhibition.
Neladalkib is designed to be highly brain-penetrant, addressing a significant clinical need for patients whose cancer has spread to the central nervous system. Nuvalent continues to enroll participants in the ALKOVE-1 study for other ALK-positive solid tumors and plans to present detailed results from the NSCLC cohort at an upcoming medical meeting.
Nuvalent is a clinical-stage biopharmaceutical company that develops precisely targeted small molecule therapies for cancer. By using structure-based drug design, the firm creates innovative treatments for kinase targets designed to overcome resistance, address brain metastases, and minimize adverse effects.
3. StandardAero Inc. (NYSE:SARO)
Average Upside Potential: 42.92%
StandardAero Inc. (NYSE:SARO) is one of the best up and coming stocks with highest upside potential. On March 31, StandardAero appointed Giovanni Spitale as President of its Business Aviation segment, effective immediately. Spitale brings over 30 years of global leadership experience to the role, having previously served as CEO of Davis Standard and held senior executive positions at The Boeing Company, GE Aviation, and Honeywell. Based at the company’s Scottsdale headquarters, he will report to COO Kim Ernzen and focus on driving strategic growth and operational excellence for the division.
Spitale succeeds Anthony Brancato III, who is retiring after a distinguished 40-year career in aviation, including nearly a decade at StandardAero. During his tenure, Brancato oversaw significant facility expansions and portfolio innovations while serving as a key advocate for the industry through organizations like the NBAA and GAMA. To ensure a seamless leadership transition, Brancato will remain with the company through June 2026.
A US Navy veteran with a background in nuclear engineering, Spitale is recognized for his ability to scale businesses through both organic growth and strategic acquisitions. His appointment comes at a pivotal time for StandardAero Inc. as a newly listed public company, following its successful IPO under the ticker SARO.
StandardAero Inc. is a leading independent maintenance, repair, and overhaul provider serving commercial, military, business aviation, and industrial power customers. The company is headquartered in Scottsdale, Arizona, and was founded in 1911.
2. ESAB Corp. (NYSE:ESAB)
Average Upside Potential: 44.76%
ESAB Corp. (NYSE:ESAB) is one of the best up and coming stocks with highest upside potential. On April 2, ESAB appointed R. Brent Jones as Chief Financial Officer, effective in early May. Jones, a highly experienced executive with over 30 years of financial leadership, succeeds Kevin Johnson, who is departing to join a private firm. Jones previously served as CFO for global organizations such as Avantor and Pall Corporation, and his background includes work in investment banking and corporate law.
In tandem with the leadership change, ESAB reaffirmed its full-year 2026 financial outlook, which was originally issued in February. Despite recent geopolitical volatility, the company remains confident in achieving its core organic sales growth targets. CEO Shyam P. Kambeyanda noted that Jones’s history of navigating international financial environments and delivering value through organic and inorganic growth will be instrumental in accelerating ESAB’s 2028 strategic plans.
Prior to joining ESAB Corp., Jones led the global finance organization at Avantor and directed commercial finance and operations at LifeScan. His early career is marked by high-stakes capital markets experience, including overseeing the $13.8 billion sale of Pall Corporation to Danaher.
ESAB Corp. is an industrial compounder that manufactures and supplies consumable products and equipment. These include cutting material, consumables & gas controlling solutions, and welding equipment. The company also offers software and digital solutions to enhance productivity and enable remote monitoring of welding operations.
1. GE HealthCare Technologies Inc. (NASDAQ:GEHC)
Average Upside Potential: 48.83%
GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best up and coming stocks with highest upside potential. On April 29, GE HealthCare reported total revenues of $5.1 billion for Q1 2026, marking a 7.4% increase, with organic revenue growth contributing 2.9%. This growth was fueled by strong commercial performance in the Pharmaceutical Diagnostics/PDx, Imaging, and Advanced Visualization Solutions segments.
While total organic orders rose by 1.1%, the company maintained a robust backlog of $21.8 billion and a book-to-bill ratio of 1.07 times. Additionally, the quarter was highlighted by the $2.3 billion acquisition of Intelerad, a move intended to strengthen the company’s cloud-based enterprise imaging capabilities. Despite the positive topline results, profitability was pressured by several headwinds, including a temporary PDx supplier issue that has since been resolved. GE HealthCare Technologies Inc. reported a net income margin of 7.6% and an adjusted EBIT margin of 13.5%, while diluted EPS stood at $0.85 and adjusted EPS at $0.99.
Looking ahead, GE HealthCare has reaffirmed its organic revenue growth guidance of 3.0% to 4.0% based on healthy global demand. However, the company lowered its full-year outlook for profit and free cash flow due to more pronounced inflationary pressures on memory chips, oil, and freight costs. The updated guidance now projects an adjusted EPS range of $4.80 to $5.00 and free cash flow of approximately $1.6 billion.
GE HealthCare Technologies Inc. is a healthcare company with a focus on various products, services, and digital solutions made for diagnoses and treatments. The company operates through Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Hedge Fund Resource Center